In some studies, anti-PD-1/PD-L1 molecules have been administered together with vaccine, conventional chemo- or radiotherapy for treatment of MSI-low pancreatic cancer with the aim to transform an immune-suppressive to an immune-active microenvironment [92,116,117,118,119]. The gene discussed is PDCD1; the disease is familial pancreatic carcinoma.